Researching Huntington’s Disease Treatments at MedStar Georgetown
We are committed to making the latest clinical trials and relevant research findings available to our patients and their families.
Our team of specialists is part of the Huntington Study Group, a global network of clinical researchers committed to finding better ways to treat symptoms and stop the disease via ongoing research and clinical trials.
Huntington’s Disease Clinical Trials
These studies are currently underway:
- Enroll-HD is a worldwide observational study for family members affected by Huntington’s disease, including spouses. Participants attend an annual study session at where they undergo a series of movement, behavioral and task-oriented tests, as well as a quality-of-life evaluation. Participants also may choose to donate a small volume of blood.
- First-HD will test the efficacy and side effects of an investigational drug called SD-809 ER (Extended Release). SD-809 ER works similarly to tetrabenazine, the only FDA-approved treatment for reducing involuntary body movements or chorea. This four-month clinical trial is open to those with Huntington’s disease who have not taken tetrabenazine in the last six months.
- ARC-HD will gauge safety and side effects of the investigational drug SD-809 ER (Extended Release) in subjects who currently take tetrabenazine, the only FDA-approved treatment for reducing involuntary body movements or chorea. This 14-month clinical trial is open to those with Huntington’s disease who currently take tetrabenazine, as well as roll-over subjects from the First-HD trial.
- PRIDE-HD will test the effectiveness of an investigational drug called pridopidine on movement, thinking and behavior, as well as gauge safety and side effects. This is a randomized, double-blind study in which some participants receive pridopidine while others get a placebo. The study is open to anyone age 21 years or older who has Huntington’s disease.